That's the whole point of getting regulatory approval is to prove there is "nothing wrong in the system". The pps has basically return to the price after RAP received the regulatory approval, the Creasphere announcement was what pushed to 30c and FOMO pushed it to 40c as investors thought revenue will be fast. I can't see why they wouldn't want this medical product which doesn't have any competitors, maybe they are waiting for TGA for Adult (as the market is much larger in this space) or FDA?
- Forums
- ASX - By Stock
- RAP
- 2020 The Year Of RAP
2020 The Year Of RAP, page-19
-
- There are more pages in this discussion • 1,337 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)